Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Venturutti L, Cordo Russo RI, Rivas MA, Mercogliano MF, Izzo F, Oakley RH, Pereyra MG, De Martino M, Proietti CJ, Yankilevich P, Roa JC, Guzmán P, Cortese E, Allemand DH, Huang TH, Charreau EH, Cidlowski JA, Schillaci R, Elizalde PV. Venturutti L, et al. Among authors: roa jc. Oncogene. 2016 Dec 1;35(48):6189-6202. doi: 10.1038/onc.2016.151. Epub 2016 May 9. Oncogene. 2016. PMID: 27157613 Free PMC article.
TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF, De Martino M, Venturutti L, Rivas MA, Proietti CJ, Inurrigarro G, Frahm I, Allemand DH, Deza EG, Ares S, Gercovich FG, Guzmán P, Roa JC, Elizalde PV, Schillaci R. Mercogliano MF, et al. Among authors: roa jc. Clin Cancer Res. 2017 Feb 1;23(3):636-648. doi: 10.1158/1078-0432.CCR-16-0970. Epub 2016 Oct 3. Clin Cancer Res. 2017. PMID: 27698002
Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
Mercogliano MF, Inurrigarro G, De Martino M, Venturutti L, Rivas MA, Cordo-Russo R, Proietti CJ, Fernández EA, Frahm I, Barchuk S, Allemand DH, Figurelli S, Deza EG, Ares S, Gercovich FG, Cortese E, Amasino M, Guzmán P, Roa JC, Elizalde PV, Schillaci R. Mercogliano MF, et al. Among authors: roa jc. BMC Cancer. 2017 Dec 28;17(1):895. doi: 10.1186/s12885-017-3897-x. BMC Cancer. 2017. PMID: 29281999 Free PMC article.
Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.
Venturutti L, Romero LV, Urtreger AJ, Chervo MF, Cordo Russo RI, Mercogliano MF, Inurrigarro G, Pereyra MG, Proietti CJ, Izzo F, Díaz Flaqué MC, Sundblad V, Roa JC, Guzmán P, Bal de Kier Joffé ED, Charreau EH, Schillaci R, Elizalde PV. Venturutti L, et al. Among authors: roa jc. Oncogene. 2016 Apr 28;35(17):2208-22. doi: 10.1038/onc.2015.281. Epub 2015 Jul 27. Oncogene. 2016. PMID: 26212010
Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer.
Schillaci R, Guzmán P, Cayrol F, Beguelin W, Díaz Flaqué MC, Proietti CJ, Pineda V, Palazzi J, Frahm I, Charreau EH, Maronna E, Roa JC, Elizalde PV. Schillaci R, et al. Among authors: roa jc. BMC Cancer. 2012 Feb 22;12:74. doi: 10.1186/1471-2407-12-74. BMC Cancer. 2012. PMID: 22356700 Free PMC article.
Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy.
Díaz Flaqué MC, Galigniana NM, Béguelin W, Vicario R, Proietti CJ, Russo R, Rivas MA, Tkach M, Guzmán P, Roa JC, Maronna E, Pineda V, Muñoz S, Mercogliano M, Charreau EH, Yankilevich P, Schillaci R, Elizalde PV. Díaz Flaqué MC, et al. Among authors: roa jc. Breast Cancer Res. 2013 Dec 17;15(6):R118. doi: 10.1186/bcr3587. Breast Cancer Res. 2013. PMID: 24345432 Free PMC article. Retracted.
306 results